Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Amedisys, Inc. AMED
$76.73
+$0.09 (0.12%)
На 18:00, 12 мая 2023
+108.81%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2469927840.00000000
-
week52high
131.32
-
week52low
69.36
-
Revenue
2223199000
-
P/E TTM
22
-
Beta
1.01349400
-
EPS
3.62000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 15:00
Описание компании
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| UBS | Sell | Neutral | 02 авг 2022 г. |
| Raymond James | Outperform | Outperform | 01 авг 2022 г. |
| Barclays | Overweight | Overweight | 29 июл 2022 г. |
| Benchmark | Buy | Buy | 28 июл 2022 г. |
| Truist Securities | Buy | Buy | 14 июл 2022 г. |
| Truist Securities | Buy | Buy | 05 окт 2022 г. |
| Benchmark | Buy | Buy | 03 окт 2022 г. |
| Raymond James | Market Perform | Outperform | 27 окт 2022 г. |
| Deutsche Bank | Buy | Buy | 24 окт 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 01 ноя 2022 г. |
| Stephens & Co. | Equal-Weight | Equal-Weight | 01 ноя 2022 г. |
| RBC Capital | Outperform | Outperform | 31 окт 2022 г. |
| Truist Securities | Buy | Buy | 28 окт 2022 г. |
| Stephens & Co. | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| Stephens & Co. | Equal-Weight | Equal-Weight | 11 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 05 янв 2023 г. |
| Oppenheimer | Outperform | Outperform | 19 янв 2023 г. |
| Benchmark | Buy | Buy | 25 янв 2023 г. |
| Credit Suisse | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kusserow Paul B. K. | D | 0 | 5777 | 01 февр 2023 г. |
| Kusserow Paul B. K. | D | 368249 | 2274 | 01 февр 2023 г. |
| Kusserow Paul B. K. | A | 370523 | 5777 | 01 февр 2023 г. |
| Kusserow Paul B. K. | D | 413838 | 6820 | 06 янв 2023 г. |
| Kusserow Paul B. K. | A | 420658 | 41313 | 02 янв 2023 г. |
| Ginn Scott G | A | 51516 | 23109 | 21 ноя 2022 г. |
| Muscato Nick | A | 14238 | 11555 | 21 ноя 2022 г. |
| Holton Adam Y | A | 5181 | 5181 | 20 окт 2022 г. |
| PERKINS BRUCE D | D | 18788 | 385 | 17 авг 2022 г. |
| Muscato Nick | D | 2683 | 719 | 25 июл 2022 г. |
Новостная лента
Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip
Zacks Investment Research
04 мая 2023 г. в 14:26
Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
03 мая 2023 г. в 22:47
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable
Zacks Investment Research
14 апр 2023 г. в 12:09
For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
Zacks Investment Research
04 апр 2023 г. в 09:55
Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.
Amedisys to Present at Multiple Healthcare Conferences in March
GlobeNewsWire
09 мар 2023 г. в 07:30
BATON ROUGE, La., March 09, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Paul Kusserow, Chairman and Chief Executive Officer and Scott Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer, will present at Oppenheimer's 33rd Annual Healthcare Conference on March 14th at 10:00 a.m. ET and at the Barclays Global Healthcare Conference on March 15th at 8:50 a.m. ET.